The U.S. Market for Over-the-Counter Allergy and Asthma Products

The U.S. Market for Over-the-Counter Allergy and Asthma Products


November 1, 2001
228 Pages - SKU: KLI521895
License type:
Online Download      US $3,250.00
Countries covered: United States

The U.S. Market for Over-the-Counter Allergy and Asthma Products

  enlarge
The U.S. Market for OTC Allergy and Asthma Products is a comprehensive analysis of the impact OTC drugs have made to the allergy and asthma market. This study provides a detailed market size analysis for the years 1996 - 2000 and market forecasts to the year 2006. Within the OTC Allergy and Asthma Product Market four market segments are covered, including: Allergic Rhinitis Remedies, Sinusitis Remedies, Ocular Allergy Remedies, and Asthma Products. A thorough description of respiratory conditions and diseases, treatments, and preventive care are included in this study. Trends covered in the report include the introduction of non-sedating antihistamines to the OTC market, consumer interests in self-medication, and impact of direct-to-consumer advertising. The U.S. Market for OTC Allergy and Asthma Products will provide the reader with a comprehensive analysis of allergy and asthma products currently marketed and potentially entering the market. The study focuses on the direction this market is taking and the contributing factors for continued growth. Detailed profiles of major competitors are profiled.



Download a Flyer (Acrobat Reader required)

Additional Information

Scope and Methodology

This study focuses on four general product categories, including:

  • Allergic Rhinitis Remedies;
  • Sinusitis Remedies;
  • Ocular Allergy Remedies; and
  • Asthma Products.

In addition to the four general product categories, a section is dedicated to the potential market, which includes potential prescription to over-the-counter switches, Allegra, Claritin and Zyrtec. Product categories are described in detail and the major market factors in each category are detailed. The report describes the industry, its relationship to various healthcare delivery channels, and trends for the future. The geographic scope of the report is the United States.

The research conducted by Kalorama Information included comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Person-to-person and telephone interviews were the primary method of gathering information. Interviews with over 50 key industry officials, trade association spokespersons, consultants, health care providers, and government personnel were compiled to form the primary basis of information - specifically revenue and market share data - presented in this report.

All market data pertains to the U.S. market at the manufacturers’ level. The base year for data was 2000. Historical data are provided for 1996 through 1999, with forecast data provided for 2001 through 2006. Compound annual growth rates (CAGRs) are provided for the 1996-2000, 2000-2006, and 1996-2006 periods for each industry segment covered.

Press Release

Largest OTC Market Segment on the Verge of Big Change

New York, October 17, 2001 /PR Newswire —Big changes could be in store for the over-the-counter (OTC) allergy and asthma product market in the near future, according to a new study released today from Kalorama Information and available through MarketResearch.com. Allergy and Asthma products the largest OTC segment in the United States with sales surpassing $1.7 billion last year, could be getting some company on the already crowded drugstore shelves.

The new study, The U.S. Market for Over-the-Counter Allergy and Asthma Products, identifies at least ten likely candidates for Rx-to-OTC switches in this area in the next few years. The most important category—non-sedating antihistamines such as Claritin, Allegra, and Zyrtec—will most likely be available OTC by 2003, according to the study. These allergy medications could grab upwards of 25% of the total market almost immediately after their introduction.

Although the study found modest growth to be the norm in most of the areas covered, remedies for ocular allergies posted respectable growth (near 10%) recently, and the potential OTC candidates likely to hit the market by 2003 are forecast to post healthy growth rates (over 12%) in the subsequent years.

“Modeling OTC markets is notoriously difficult,” notes Steven Heffner, Acquisitions Editor at Kalorama. “There are many more unpredictable variables to take into account than in prescription markets: consumer behavior and brand loyalty, fierce pricing competition especially in the robust generic area, and uncertain reimbursement policies from pharmacy benefits companies. Our analysts looked at consumer and regulatory trends and compiled excellent market information from both the retail unit sales side to the manufacturers’ dollar volume to analyze this complex market.”


More Allergy/Immunology reports by Kalorama Information

Retail Clinics: Consumer Attitudes Results of the 2013 Kalorama Survey by Kalorama Information
Retail Clinics: Consumer Attitudes Results of the 2013 Kalorama Survey - Retail clinics are medical settings located in a retail store. They are ...
What's Next In Vaccines (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline) by Kalorama Information
Vaccines are one of the most dynamic parts of the pharmaceutical business today but future growth will depend on a considerable amount of potential vaccines ...
The World Market for Over The Counter (OTC) Drugs by Kalorama Information
Over-the-counter (OTC), non-legend, and non-prescription are all adjectives describing drugs that an individual may purchase without a prescription.  Many pharmaceutical companies seeking more revenue and ...
The Market for Rx to OTC Switches, 5th Editiion by Kalorama Information
While many areas of the pharmaceutical industry will suffer from current economic conditions worldwide, sales of over-the-counter drugs are widely anticipated to grow as consumers ...
See all reports like this >>

More United States Allergy/Immunology reports

The 2013-2018 Outlook for Food-Allergy and Intolerance Products in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Food-Allergy and Intolerance Products in the United StatesThis econometric study covers the latent demand outlook for food-allergy and intolerance products across ...
The 2013-2018 Outlook for Cold, Cough, and Sore Throat Medications in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Cold, Cough, and Sore Throat Medications in the United StatesThis econometric study covers the latent demand outlook for cold, cough, and ...
The 2013-2018 Outlook for Allergy Drugs in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Allergy Drugs in the United StatesThis econometric study covers the latent demand outlook for allergy drugs across the states and cities ...
Consumer Health in the US by Euromonitor International
Consumer Health in the USDespite major recalls and a weak cold and flu season further dragging down over-the-counter (OTC) sales, overall consumer health grew over ...
See all reports like this >>

More United States reports

The 2013-2018 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in the United StatesThis econometric study covers the latent demand outlook for collagen and (hyaluronic ...
The 2013-2018 Outlook for Relish in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for relish across the states and cities of the United States. Latent demand (in millions of U.S. ...
The 2013-2018 Outlook for Indian Breads in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for Indian breads across the states and cities of the United States. Latent demand (in millions of ...
D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
See all reports like this >>